Jeff Bird focuses on healthcare, including biotechnology and medical devices.

He is currently a board member at Artemis Health (noninvasive prenatal diagnosis), Drais Pharmaceuticals (oncology therapeutics), Horizon Therapeutics (novel fixed dose drug combinations), NuGen Technologies (research reagents), Portola Pharmaceuticals (a spin-out of Cor/Millennium focused on cardiovascular therapeutics), Restoration Robotics (aesthetic surgery devices), Roxro Pharma (pain therapeutics), Threshold Pharmaceuticals (oncology therapeutics, NASDAQ: THLD), ViroBay, Inc. (HCV therapeutics) and Xoft Inc. (cancer radiation devices). He also represents the firm’s investments in Acceleron Pharmaceuticals (metabolic therapeutics), Ameritox (pain therapeutic drug monitoring), Barrx (gastrointestinal devices), and Pacific Biosciences (DNA sequencing).

Jeff was formerly a director at Akarx Inc., which was acquired by MGI Pharma in 2008, and Idun Pharmaceuticals, which was acquired by Pfizer in 2005.

Jeff was previously Senior Vice President, Business Operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He was primarily responsible for several alliances with major pharmaceutical companies and helped Gilead to acquire NeXstar in a $550 million transaction. His commercial responsibilities included direct sales in the US and Europe.

Jeff received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School.